Immuneering is developing groundbreaking patient stratification technology to pre-identify patients who will respond to specific therapies.

News: Immuneering, Developer of Personalized Cancer Test, Selected as First Life Sciences Startup in Dog Patch Incubator (Xconomy)
News: Immuneering, Led by Young CEO and Mentor, Aims to Pick Which Cancer Drugs Should Work (Xconomy)
News: Immuneering heads to the dog patch (MassDevice)
News: Immuneering Corp. Profile (Windhover/Start-Up)
News: New software may improve odds of drug discovery (Fierce BioResearcher)
News: Software to help biotechs' drug effectiveness (Mass High Tech)
News: NIH stimulus likely boon for area colleges, biotechs (Boston Business Journal)
News: The Climate for Early-Stage Life Sciences Startups (Xconomy)
News: Immuneering Tests Another Path for Personalized Medicine (Mass High Tech)

Events: Immuneering Showcased at The 2009 Massachusetts State Legislature Innovation Day: Oct. 15, 2009
Events: Immuneering Selected to Present at The 2009 MassBio Investors Forum: Oct. 6, 2009
Events: Immuneering Selected to Present at The 2009 MassMEDIC Investors Conference: Oct. 2, 2009
Events: Immuneering Selected to Present at The 2009 New York Venture Summit
Events: Immuneering Selected for Bio-IT World Conference Panel on "Clinical Application of Personalized Medicine"
Events: Immuneering Invited to Present at Massachusetts Early-Stage Life Sciences Technology Conference

Using parameters measured from blood and tumor samples with existing instruments, Immuneering’s proprietary computational models decode the dynamics of a patient’s immune system in order to predict how that patient will respond to particular therapies.